6879-01-2 Usage
Description
Tuberostemonine, a novel alkaloid, has been isolated from Sternona sessilifolia and S. tuberosa. It was initially given the formula C19H29O4N, which was later revised. tuberostemonine crystallizes in colorless needles from MeOH with 1 mole of solvent, has a melting point of 65-88°C (dec.), and exhibits a specific optical rotation of [α]D 25.4° (Me2CO). Tuberostemonine is a non-phenolic, tertiary base that forms various salts such as hydrobromide, perchlorate, methiodide monohydrate, methochloride dihydrate, and methosulphate with distinct melting points. It does not hydrolyze under acidic conditions but can be converted to a dihydro derivative in the presence of excess PtO2. Oxidation reactions with KMnO4 and silver oxide yield different compounds, with the latter still containing lactone groups and giving a positive Ehrlich pyrrole reaction. It is a natural product found in Stemona phyllantha and Stemona tuberosa.
Uses
Used in Pharmaceutical Applications:
Tuberostemonine is used as a therapeutic agent for treating cigarette smoke-induced acute lung inflammation. Its presence as one of the major components of Radix Stemonae contributes to its medicinal value, making it a promising candidate for further research and development in the pharmaceutical industry.
Used in Traditional Medicine:
As a component of Radix Stemonae, tuberostemonine is utilized in traditional medicine for its various therapeutic effects. Its presence in the plant material has been recognized for centuries, and it continues to be an essential part of herbal remedies and treatments.
Used in Chemical Research:
Tuberostemonine's unique chemical properties and reactivity make it an interesting subject for chemical research. Its various salts, melting points, and reactions with different reagents provide valuable information for understanding its structure and potential applications in the field of chemistry.
Used in Drug Development:
The therapeutic effects of tuberostemonine against cigarette smoke-induced acute lung inflammation suggest its potential use in drug development. Further research and development could lead to the creation of new drugs or therapies targeting lung inflammation and related conditions, benefiting patients suffering from respiratory issues.
References
Kondo, Suzuki, Satomi.,J. Pharrn. Soc., Japan, 54,96 (1934)
Kondo, Suzuki, Satomi., ibid, 59, 177 (1939)
Kondo, Suzuki, Satomi., ibid, 60, 149 (1940)
Kondo, Suzuki, Satomi., ibid, 61, 111 (1941)
Kaneko., Ann. Rep. ITSUU Lab. (Tokyo), 11,45 (1960)
Gotz, Bogri, Gray., Tetrahedron Lett., 707 (1961)
Edwards, Feniak, Handa., Can. J. Chern., 40,455,2416 (1962)
Crystal structure:
Harada et ai., Chern. Cornrnun., 460 (1967)
Check Digit Verification of cas no
The CAS Registry Mumber 6879-01-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,8,7 and 9 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 6879-01:
(6*6)+(5*8)+(4*7)+(3*9)+(2*0)+(1*1)=132
132 % 10 = 2
So 6879-01-2 is a valid CAS Registry Number.
InChI:InChI=1/C22H33NO4/c1-4-13-14-7-5-6-8-23-16(17-9-11(2)21(24)26-17)10-15(19(14)23)18-12(3)22(25)27-20(13)18/h11-20H,4-10H2,1-3H3
6879-01-2Relevant articles and documents
Asymmetric total syntheses of tuberostemonine, didehydrotuberostemonine, and 13-epituberostemonine
Wipf, Peter,Spencer, Stacey R.
, p. 225 - 235 (2007/10/03)
Detailed experimental approaches toward the pentacyclic Stemona alkaloids tuberostemonine and didehydrotuberostemonine and the close analogue 13-epituberostemonine are described. The syntheses originate with a hydroindolinone derivative that can be obtain
